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ARTICLE
Association study in African-admixed populations
across the Americas recapitulates asthma risk loci
in non-African populations
Michelle Daya et al.#
Asthma is a complex disease with striking disparities across racial and ethnic groups. Despite
its relatively high burden, representation of individuals of African ancestry in asthma genome-
wide association studies (GWAS) has been inadequate, and true associations in these
underrepresented minority groups have been inconclusive. We report the results of a
genome-wide meta-analysis from the Consortium on Asthma among African Ancestry
Populations (CAAPA; 7009 asthma cases, 7645 controls). We find strong evidence for
association at four previously reported asthma loci whose discovery was driven largely by
non-African populations, including the chromosome 17q12–q21 locus and the chr12q13 region,
a novel (and not previously replicated) asthma locus recently identified by the Trans-National
Asthma Genetic Consortium (TAGC). An additional seven loci reported by TAGC show
marginal evidence for association in CAAPA. We also identify two novel loci (8p23 and
8q24) that may be specific to asthma risk in African ancestry populations.
Corrected: Author correction
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Asthma is a complex disease where the interplay betweengenetic factors and environmental exposures controlssusceptibility and disease progression. In the U.S., ethnic
minorities are disproportionally affected by asthma. For example,
African Americans and Puerto Ricans have higher asthma-related
morbidity and mortality rates compared to European Amer-
icans1–3. In addition to environmental, cultural, and socio-
economic risk factors, genetic factors, possibly from a common
background ancestry, likely underlie some of these disparities in
the health burden of asthma in the U.S. Despite the relatively high
burden of disease, representation of African ancestry populations
in asthma genome-wide association studies (GWAS) has been
limited, and in GWAS’s performed to date including individuals
of African ancestry, the samples have been modest and under-
powered to detect true associations. For example, the largest
asthma GWAS focused solely on African ancestry populations
included only 819 asthma cases4. Recently, the Trans-National
Asthma Genetic Consortium (TAGC) reported 18 asthma-
associated loci based on a meta-analysis of 142,486 subjects, but
only 2149 cases and 6055 controls included in this study were of
African ancestry. Only two genome-wide significant
associations5,6 have been reported for asthma from GWAS con-
ducted in African ancestry populations to date4–8. The discovery
of genetic risk factors for asthma in African ancestry populations
has been further hampered by lack of representation of African
ancestry in imputation reference panels, and legacy commercial
genotyping arrays that have until very recently not provided
adequate coverage of linkage disequilibrium (LD) patterns in
African ancestry populations.
To address these disparities in asthma genetics research and
the paucity of information on African genetic diversity, we pre-
viously established the Consortium on Asthma among African
ancestry Populations in the Americas (CAAPA)9. Because of the
lack of adequate representation of African ancestry in imputation
reference panels, we first performed whole-genome sequencing
(WGS) of samples collected from 880 individuals who self-
reported African ancestry from 19 North, Central and South
American and Caribbean populations (446 individuals from nine
African American populations, 43 individuals from Central
America, 121 individuals from three South American popula-
tions, and 197 individuals from four Caribbean populations), as
well as individuals from continental West Africa (45 Yoruba-
speaking individuals from Ibadan, Nigeria and 28 individuals
from Gabon). These whole-genome sequences were made pub-
licly available through dbGAP (accession code phs001123.v1.p1)
and were incorporated into the reference panel on the Michigan
imputation server (a free genotype imputation service, https://
imputationserver.sph.umich.edu).
Previously we performed coverage analysis of the novel var-
iation identified in the CAAPA sequence data, and found only
69% of common SNP variants and 41% of low-frequency SNP
variants identified by CAAPA can be tagged by traditional GWAS
arrays at r2 ≥ 0.810. In addition, lack of coverage of low frequency
variants (minor allele frequency [MAF] between 0.01–0.05) in
GWAS arrays negatively impacts the imputation of low frequency
variants. To address these issues, we used the CAAPA sequence
data to develop the African Diaspora Power Chip (ADPC) in
partnership with Illumina, Inc., a gene-centric SNP genotyping
array designed to complement commercially available genome-
wide chips, thereby improving tagging and coverage of African
ancestry genetic variation10. The array included ~495,000 SNPs,
with a MAF enriched for low frequency variants. Subsequently,
the content of the ADPC was incorporated into Illumina’s Multi-
Ethnic Global Array (MEGA)10.
Using the ADPC, we genotyped CAAPA participants from
nine studies (seven African American studies, one African
Caribbean [Barbados], and one South American [Puerto Rico]).
We combined the ADPC data with existing commercial genome-
wide genotype data, and imputed additional genotypes using the
CAAPA reference panel. Subsequently we used the MEGA to
genotype additional African ancestry asthma studies with no
previously existing genome-wide genotype data (one African
American, three South American, and two Caribbean studies),
and similarly imputed genotypes on these subjects using the
CAAPA reference panel. Sample populations, their ascertain-
ment, and clinical characteristics are described in detail in the
Supplementary Note 1, Table 1 and Supplementary Table 1. We
then used these data to perform a GWAS of asthma in individuals
of African ancestry (7009 asthmatic cases and 7645 controls). We
also performed admixture mapping, a technique that leverages
local ancestry to identify regions of the genome where ancestry
from a particular ancestral population is inherited more fre-
quently among affected compared to unaffected individuals.
Our GWAS results recapitulate 11 of the 18 loci recently
reported by TAGC, including the chromosome 9p24 (IL33),
15q22 (RORA), and 17q12–q21 loci, as well as a locus on chro-
mosome 12q13 (STAT6) reported as novel but not replicated by
TAGC. We identify two loci on chromosome 8 not previously
reported as being associated with asthma, and one local ancestry
peak on chromosome 6q22 is genome-wide significant in our
admixture mapping study. We speculate that the common
asthma-associated variants on chromosome 8p23 implicate the
ARHGEF10 or MYOM2 genes, while a low frequency protective
variant on chromosome 8q24 is intronic to TATDN1, a gene with
increased expression in human airway smooth muscle cells sti-
mulated with interleukin. The TCF21 gene, which has previously
been shown to be differentially expressed in bronchial biopsies of
asthmatics compared to controls, is a likely candidate in the
admixture mapping peak. However, further replication efforts are
necessary to provide robust evidence of replication for these
chromosome 6 and 8 loci.
Results
Association analysis. Studies included in the asthma association
analysis represent a diverse spectrum of African ancestry (Fig. 1a,
Supplementary Fig. 1, Supplementary Table 2) with median
African ancestry proportions in non-asthmatics as low as 0.17 in
subjects from Puerto Rico (GALA II) and as high as 0.90
in subjects from Jamaica and Barbados (JAAS and BAGS). In
addition, the studies had different objectives and differed
in potentially relevant factors such as age of onset and diagnostic
criteria (see Supplementary Note 1 and Supplementary Table 1).
For this reason, we performed tests for association separately for
each dataset, and then combined the results using MR-MEGA, a
novel meta-analysis approach that models allelic effects as a
function of axes of genetic variation11. In this way, heterogeneous
associations across genetically distinct populations are not
penalized, and the degree of heterogeneity due to ancestry, as well
as residual effects due to differences in study design, can be
assessed. The results of the genome-wide meta-analysis are
summarized in Fig. 1b and c, and associations with MR-MEGA
association p < 10−6 (the same cut-off employed by the EVE
GWAS6) are summarized in Table 2 and Supplementary Table 9.
There were seven loci with associations smaller than this
threshold. Associations at two loci were genome-wide significant
(p < 5 × 10−8), including a locus at chromosome 8p23 not pre-
viously reported by any asthma GWAS7,12, and the chromosome
17q12–q21 locus, which is regarded as one of the most consistent
asthma association findings to date13. Two of the loci with
p < 10−6 (but not attaining conventional genome-wide sig-
nificance) were reported recently by TAGC in the multi-ethnic
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meta-analysis of 23,948 asthmatics and 118,538 controls6. The
remaining three loci involved low-frequency SNPs (MAF between
0.01–0.05), and the accuracy of SNP imputation could only be
verified for one locus on chromosome 8q24 (Supplementary
Table 10).
Associations novel to CAAPA. Several SNPs intronic to a gene
encoding a long non-coding RNA on chromosome 8p23 have
MR-MEGA association p < 10−6, and two of these associations
were genome-wide significant. While this association was
observed in multiple African American samples, the strongest
effects were observed in three non-U.S. studies from Barbados
(BAGS), Cartagena, Colombia (PGCA), and Puerto Rico (GALA
II; Supplementary Fig. 15). While the associated SNPs in this
region do not overlap with any expression quantitative trait locis
(eQTLs) in the publicly available databases we mined, long-range
chromatin interaction and expression data in relevant tissues
(lymphoblastoid cells, fetal lung fibroblast cells, and lung)
implicate two different genes, ARHGEF10 and MYOM2,
~600–800 KB downstream from the most significant SNP
rs13277810 that potentially explain these observed associations
(Supplementary Note 13, Supplementary Fig. 19)14–16. Expres-
sion of ARHGEF10 has been associated with exacerbations in
chronic obstructive pulmonary disease17, and this gene may also
be a target of the well-known type-2 inflammation cytokine
interleukin 3318, while genetic variants in MYOM2 are predictive
of lung function in an isolated European ancestry (Hutterite)
population19. We tested whether SNP rs13277810 is associated
with asthma using African American genetic data from three
cardiovascular studies as well as African American and Hispanic
genetic data from the BioMe biobank. Although there was strong
evidence for replication of this SNP association in BioMe His-
panics (SNP association Z-score p= 7.15 × 10−4, with consistent
effect direction), the SNP was not associated with asthma in any
of the other studies, and the TAGC asthma GWAS summary
statistics also did not support this association in Europeans
(Table 3). Most CAAPA asthmatics had childhood onset asthma
(Supplementary Table 1), which is likely not the case for the
cardiovascular disease studies. Roughly a third of BioMe His-
panics are Puerto Rican (Supplementary Note 2), and Puerto
Rican asthmatics are likely to have childhood onset asthma20. We
therefore re-tested this association in CAAPA, and compared
results when including versus excluding adult onset asthmatics.
Because the effect size of the association decreased when adult
onset asthmatics were excluded (Supplementary Table 17), we
could not confirm that age of asthma onset accounts for the lack
of replication. Despite the potential biological plausibility of this
chromosome 8p23 association, it may be a false positive. Alter-
natively, lack of replication could be due to differences in study
design (ascertainment of subjects and asthma case-control clas-
sification), stronger effects in non-U.S. African ancestry popula-
tions, and the small number of asthmatics available in the
replication data.
The remaining three loci yielding MR-MEGA association p <
10−6 have not previously been reported by any asthma GWAS,
and the identified SNPs were all low frequency variants (0.01 <
MAF < 0.05). According to allele frequencies from the 1000
Genomes Project (TGP), these SNPs are present in African but
not European populations. The imputation quality of the most
significant SNPs at these regions is only moderate (median RSQ
statistics of 0.79, 0.61, and 0.77 for rs114647118 [8q24],
rs73952947 [18q12], and rs73595000 [19q13], respectively, see
Supplementary Data 1); therefore we performed TaqMan
genotyping to confirm results in the JAAS (Jamaica) and BAGS
(Barbados) samples (Supplementary Table 10). The veracity of
imputation and asthma association could only be verified for
rs114647118 on chromosome 8q24 (Supplementary Tables 10
and 11). Carriers of the minor allele at SNP rs114647118 were less
likely to have asthma, and this pattern was observed in all
CAAPA studies (Supplementary Fig. 15). SNP rs114647118 is
intronic to TATDN1, a gene with increased expression in human
airway smooth muscle cells stimulated with interleukin 17A21.
However, this association did not replicate in the three African
American cardiovascular studies (Table 3). Unfortunately, data
were not available in TAGC or BioMe to test for replication.
Comparison to previous asthma GWAS. We compared results
from the recent TAGC multi-ethnic meta-analysis, the largest and
most definitive GWAS performed in observed asthma cases and
controls to date, with the CAAPA meta-analysis7. TAGC reported
18 loci associated with asthma, categorizing nine loci as known
asthma susceptibility genes (known), five as new asthma loci
(new), two as new signals at loci previously associated with
asthma in ancestry-specific populations (ancestry-specific), plus
Table 1 Studies included in the CAAPA association analysis
Population Location Study GWAS platform Non-asthmatics Asthmatics Total Nr SNPs
African American Baltimore BASS Illumina MEGA 216 135 351 12,403,613
Baltimore GRAAD(1) ADPC+ Illumina HumanHap 650Y 385 396 781 15,486,076
Baltimore GRAAD(2) ADPC+ Illumina OMNI 2.5 23 65 88 7,496,303
Chicago CAG ADPC+ Illumina HumanHap1M 156 114 270 11,604,736
Detroit SAPPHIRE ADPCa+Affymetrix Axiom AFR 566 1325 1891 18,768,360
Jackson JHS(1) ADPC+Affymetrix 6.0 283 44 327 12,124,436
Jackson JHS(2) ADPC+Affymetrix 6.0 546 101 647 14,777,976
San Francisco SAGE II ADPC+Affymetrix Axiom LAT 691 1001 1692 18,008,099
Washington HUFS ADPC+Affymetrix 6.0 1527 303 1830 18,102,295
Winston-Salem SARP ADPC+ Illumina HumanOmniExpress+
HumanHap1M
45 302 347 12,281,618
4438 3786 8224
Barbados Barbados BAGS ADPC+ Illumina HumanHap 650Y 338 282 620 14,546,148
Brazil Condé BIAS Illumina MEGA 426 194 620 13,663,002
Brazil Salvador ProAR Illumina MEGA 346 761 1107 15,963,442
Colombia Cartagena PGCA Illumina MEGA 488 664 1152 15,093,107
Honduras Honduras HONDAS Illumina MEGA 249 254 503 12,895,713
Jamaica Jamaica JAAS Illumina MEGA 507 167 674 14,792,220
Puerto Rico Puerto Rico GALA II ADPC+Affymetrix Axiom LAT 853 901 1754 15,125,996
7645 7009 14,654 23,328,733
The table summarizes the geographical location and final number of subjects and imputed SNPs included in the asthma association analysis. Bold numbers are the sum of the numbers above.
aADPC data available for 730 asthmatics only
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two as asthma signals previously reported for asthma with hay fever
(asthma+ hay fever) (Table 2 and Supplementary Table 12)7.
Because some of the CAAPA studies were included in the TAGC
asthma meta-analysis (of the 2149 asthmatics and 6055 non-
asthmatics in TAGC, 1601 asthmatics and 2375 non-asthmatics
were from studies included in the CAAPA discovery, and 548
asthmatics and 3680 non-asthmatics were from studies included in
the CAAPA replication), and to contrast African and European
asthma susceptibility loci, we compared CAAPA associations with
those observed in TAGC Europeans. Only two of the TAGC loci,
on chromosome 12q13 and 5q31.1, were not genome-wide sig-
nificant in TAGC Europeans as judged by their random effect
p-values (p= 1.6 × 10−7 and p= 1.6 × 10−6, respectively), although
the fixed-effect p-values for these associations were genome-wide
significant (p= 5.5 × 10−9 and p= 8.5 × 10−10, respectively). Both
these loci were not reported by any prior GWAS of asthma, and
their p-values in the other ethnic groups represented in TAGC were
marginal (p= 0.05, 0.22, and 0.60 for the chromosome 12q13
TAGC lead SNP and p= 0.04, 5.5 × 10−3, and 0.27 for the chro-
mosome 5q31.1 TAGC lead SNP in Africans, Japanese, and Latinos,
respectively). We therefore conclude the genome-wide significance
of these loci in the TAGC multi-ethnic meta-analysis is largely due
to their strong associations observed in subjects of European
ancestry.
TAGC summary statistics were merged with the CAAPA meta-
analysis results, and associations of 810 SNPs with significant
fixed-effect p-values in TAGC Europeans, Bonferroni corrected
for the number of overlapping SNPs in the merged dataset, were
assessed for replication in the CAAPA meta-analysis. Three
known asthma loci replicated in CAAPA, after a Bonferroni
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Fig. 1 Summary of CAAPA ancestry and meta-analysis results. a CAAPA ADMIXTURE estimates: this panel summarizes the genome-wide proportions of
ancestry for K= 3 populations, as estimated by the software program ADMIXTURE. A combined dataset of 20,482 overlapping and linkage disequilibrium
pruned SNPs in 84 African (YRI, blue) and 84 European (CEU, red) 1000 Genomes Project phase 3 subjects, 43 Native American (green) subjects and
12,223 putatively unrelated CAAPA subjects were used to estimate these ancestry proportions. b QQ plot of the meta-analysis p-values: the plots in this
panel are stratified by minor allele frequency (MAF) for low frequency and common SNPs. Inflation factors were calculated by transforming MR-MEGA
association p-values to 1 degree of freedom (df) Chi-square statistics, and dividing the median of these statistics by the median of the theoretical Chi-
square (1 df) distribution. The dashed black and red lines represent the upper and lower 95% confidence interval. c Manhattan plot of the meta-analysis
p-values: the red, blue, and green horizontal lines in the Manhattan plot represent significant (MR-MEGA association p < 5 × 10−8), suggestive (MR-MEGA
association p < 10−6), and candidate gene (MR-MEGA association p < 2.6 × 10−3) value thresholds, respectively. The candidate gene threshold is a
Bonferroni-adjusted alpha level for 20 tests (1 locus from EVE, 1 locus from eMERGE, and 18 loci from TAGC). Windows of ±10 KB around the lead SNP at
each selected locus are colored blue (EVE and eMERGE loci), red (TAGC loci), and purple (CAAPA loci with lead SNPs having p < 10−6). A larger window
of ±200 KB is shown for the chromosome 17q12–21 locus
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correction for 810 association tests: chromosomes 9p24
(RANBP6, IL33), 15q22 (RORA,NARG2,VPS13C), and
17q12–q21 (Supplementary Table 13).
The TAGC lead SNP rs167769 on chromosome 12q13 is
intronic to STAT6, a transcription factor that affects Th2
lymphocyte responses mediated by IL-4 and IL-137,22. This was
a new association reported by TAGC, not previously implicated
in any asthma GWAS, although we note this SNP has been
reported as a putatively causal SNP discovered by GWAS of lung
function23,24, and a number of linkage studies have pinpointed
this chromosomal region in the early days of genome-wide
investigations of asthma and atopy25–28. In addition, markers in
STAT6 have been identified by a number of candidate gene
association studies29–32. However, prior to the CAAPA analyses,
this locus had not been replicated in independent asthma GWAS
datasets. The lead SNP rs3122929 in CAAPA at this locus is in
strong LD with the TAGC lead SNP rs167769 in Europeans from
the TGP (r2= 0.93) and nearly achieves genome-wide signifi-
cance in CAAPA (MR-MEGA association p= 9.1 × 10−7). In
addition, the association observed in TAGC subjects of African
ancestry was marginal (fixed effect p= 0.05). With the increased
sample size available through CAAPA, our meta-analysis
provides further evidence of the association between the 12q13
region and asthma, confirming its contribution to asthma risk in
African ancestry populations.
We also assessed windows ±10 KB from each of the 18 TAGC
lead SNPs for replication in CAAPA (±200 KB for the
chr17q12–q21 locus, due to the extended LD in this region), as
well as 2 SNPs previously reported as achieving genome-wide
significance in African ancestry populations5,6 (Fig. 1c). Con-
sidering a Bonferroni-corrected significance threshold for 20 tests
(one for each of these prior loci), an additional seven TAGC loci
showed evidence of association in the CAAPA meta-analysis
(Table 2, loci not in bold font). This includes a novel TAGC locus
on chromosome 6p21 implicating human leukocyte antigen
genes. In addition, for the known chromosome 5q31 TAGC locus,
one of the CAAPA associations passing this significance thresh-
old involved a SNP in strong LD with the TAGC lead SNP in
TGP Europeans (rs1295686, r2 with TAGC lead SNP rs20541=
0.96, Supplementary Table 18).
The genome-wide meta-analysis of asthma in multi-ethnic
populations previously performed by the EVE consortium
reported a genome-wide significant African ancestry-specific
association for SNP rs1101999, which is intronic to the PYHIN1
gene6. This was the first African ancestry asthma association
reported by a GWAS. This SNP has a high minor allele frequency
in African populations (0.31 in the TGP phase 3 AFR population,
n= 1322), but a very rare or low frequency in other populations
(MAF < 0.005 in TGP phase 3 EAS, EUR, and SAS, n= 1008,
1006, and 978, respectively, MAF= 0.04 in AMR, n= 694), and
the role this gene may play in asthma remains unclear. SNP
rs1101999 was marginally associated with asthma in the CAAPA
meta-analysis (MR-MEGA association p= 6.4 × 10−3), but the
strength of association was much reduced from its original report
(Supplementary Fig. 13, Supplementary Tables 12 and 14).
Recently, the eMERGE (electronic medical records and genomics)
network conducted an asthma GWAS in biobank subjects, and
reported one genome-wide significant association in African
Americans, SNP rs11788591, intronic to the PTGES gene. This
association did not replicate in the CAAPA meta-analysis (MR-
MEGA association p= 0.23, Supplementary Table 12, Fig. 1c,
Supplementary Fig. 13).
Genome-wide significant associations on chr17q12–q21.
Associations between SNPs on chr17q12–21 and risk of asthma
showed evidence of ancestry heterogeneity (46 of the 54 SNPs
with association p < 10−6 had significant heterogeneity, p < 0.05).
In general, the magnitude of the effect size increases as the
average proportion of European ancestry in the study increased
(Supplementary Table 9; most of the corresponding ß0 values
were close to zero, whereas ß1, which captures the effect along the
axis of genetic variation separating African and European
ancestry, showed an increase in effect size magnitude as European
ancestry increased). We also observe that the higher the average
proportion of African ancestry, the smaller the magnitude of the
effect size (Fig. 2b, forest plot of the lead association ordered by
average African ancestry). An exception was observed among
Honduran subjects who self-reported as Garifuna (HONDAS).
HONDAS has a large average African (77%), a higher Native
Table 2 Lead SNP summary
CAAPA TAGC
GWAS Locus Descr. rsID hg19 position Genes RA/EA EAF OR [95% CI] P EAF OR [95% CI] P
CAAPA 8p23 new rs13277810 2,550,802 LOC101927815
(intronic)
C/T 0.12 1.26 [1.17-1.37] 3.2×10-8 0.19
8q24 new rs114647118 125,531,353 TATDN1 (intronic) C/T 0.01 0.48 [0.37-0.63] 2.7×10-7 0.00
12q13 known rs3122929 57,509,102 STAT6, LRP1
(intergenic)
C/T 0.27 1.17 [1.10-1.24] 9.1×10-7 0.34
15q22 known rs10519067 61,068,347 RORA (intronic) G/A 0.29 0.85 [0.80-0.90] 1.8×10-7 0.14 0.89 [0.85-0.92] 8.3x10-9
17q12-21 known rs907092 37,922,259 ORMDL3,GSDMB,
ZPBP2,ERBB2
G/A 0.20 0.80 [0.75-0.85] 4.3×10-12 0.47 1.08 [1.05-1.11] 3.3x10-9
TAGC 2q12 known rs1420101 102,957,716 IL1RL1,IL1RL2, IL18R1 C/T 0.33 1.07 [1.02-1.13] 0.03 0.37 1.12 [1.10-1.15] 9.1x10-20
5q22.1 known rs10455025 110,404,999 SLC25A46,TSLP A/C 0.12 1.11 [1.01-1.22] 0.05 0.34 1.15 [1.12-1.18] 2.0x10-25
5q31 known rs20541 131,995,964 IL13,RAD50,IL4 A/G 0.79 0.95 [0.89-1.02] 0.27 0.79 0.89 [0.86-0.91] 1.4x10-14
6p22 new rs1233578 28,712,247 GPX5,TRIM27 A/G 0.35 1.02 [0.97-1.08] 0.32 0.13 1.11 [1.07-1.15] 5.3x10-9
6p21 known rs9272346 32,604,372 HLA-DRB1, HLA-
DQA1
G/A 0.56 1.07 [1.02-1.13] 0.03 0.56 1.16 [1.13-1.19] 4.8x10-28
9p24 known rs992969 6,209,697 RANBP6,IL33 A/G 0.70 0.88 [0.84-0.94] 1.1x10-4 0.75 0.85 [0.82-0.88] 1.1x10-17
11q13 known rs7927894 76,301,316 C11orf30,LRRC32 C/T 0.34 1.08 [1.02-1.14] 9.0x10-3 0.37 1.10 [1.07-1.13] 3.5x10-11
12q13 new rs167769 57,503,775 STAT6,NAB2,LRP1 C/T 0.22 1.11 [1.04-1.19] 6.9x10-4 0.40 1.08 [1.05-1.11] 1.6x10-7
15q22 known rs11071558 61,069,421 RORA,NARG2,
VPS13C
A/G 0.14 0.89 [0.85-0.92] 1.9x10-10
15q22 known rs2033784 67,449,660 SMAD3,SMAD6,
AAGAB
A/G 0.42 1.04 [0.99-1.10] 0.23 0.30 1.11 [1.08-1.14] 2.5x10-14
17q12-21 known rs2952156 37,876,835 ERBB2,PGAP3,
C17orf37
A/G 0.58 0.92 [0.87-0.97] 0.01 0.70 0.86 [0.84-0.88] 7.6x10-29
CAAPA lead SNPs (MR-MEGA association p < 10−6) and genome-wide significant associations reported by TAGC with evidence for replication in CAAPA are listed. Because some of the CAAPA studies
were included in the TAGC asthma meta-analysis, and in order to contrast African and European asthma susceptibility loci, the table summarizes the associations in TAGC Europeans only (statistics from
the TAGC random effects analysis, reported for the CAAPA and TAGC results). TAGC loci with strong evidence for association in CAAPA are highlighted in bold font. 1000 Genomes Project phase III
European allele frequencies are reported as the estimated EAF for TAGC Europeans
New asthma GWAS result not reported prior to the corresponding GWAS, Known asthma GWAS result reported prior to the corresponding GWAS. RA reference allele, EA effect allele, EAF effect allele
frequency, P P asthma association
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American (20%), and a very small European component (3%).
Interestingly, the lead SNP in CAAPA was the same SNP
reported by a meta-analysis of asthma in Puerto Rican children33,
distinct from the lead SNPs reported by the multi-ethnic EVE and
TAGC GWAS6,7. The most significant and largest effect size
magnitudes were observed for the studies that had higher Eur-
opean and Native American components; however, we speculate
that this may reflect risk for asthma inherited from a Native
American genetic background given the minimal European
component in the HONDAS population. We note this trend is
not as strong in PGCA, the CAAPA study with the highest
proportion of Native American ancestry (29%), which may be
due in part to the heterogeneous patterns of LD in this
chromosomal region.
In addition to the smaller effect size magnitude in studies with
high African ancestry, we also observed much weaker associations
(Supplementary Fig. 11 vs. Supplementary Fig. 12), and no
chr17q12–q21 associations with p < 10−6 were observed in an
inverse-variance meta-analysis of African American samples
(Supplementary Table 4), despite a relatively large sample size
of 3651 cases and 4222 controls. These observations are
consistent with a recent report by Stein et al. summarizing the
chromosome 17q12–q21 locus, which included an analysis and
discussion of the relatively weak associations observed at this
locus among African Americans13. They posited that the reduced
strength of association may be due to an overall lower MAF
spectrum in African Americans in this region (which reduces
statistical power to detect association), breakdown of LD on
African haplotypes, and different asthma endotypes (viral
exposures) in children. Based on the reduced effect size
magnitude observed in studies with higher average African
ancestry, we additionally posit a smaller effect size magnitude is
observed on African ancestry haplotypes (which could in turn be
due to breakdown of LD and reduced correlation between tagging
and causal variants). To investigate this, we extracted 17
putatively causal SNPs reported in the Stein et al. review, plus
an additional five SNPs from the CAAPA meta-analysis with MR-
MEGA association p < 10−6 and r2 < 0.8 between all 17 SNPs in
TGP European and African populations. We then stratified
subjects for whom local ancestry estimates were available based
on the number of copies of African ancestry at each of these
SNPs, and tested for association between each SNP and asthma
separately for each local ancestry group (0, 1, or 2 copies of
African ancestry, Supplementary Data 2). Figure 2c shows a trend
of decreasing effect size magnitude as the number of copies of
African ancestry increased, for most of these 22 candidate SNPs,
suggesting (but not conclusively proving) smaller effect size
magnitudes on African ancestry haplotypes.
Consistent with Stein et al., the degree to which LD breaks
down in CAAPA samples increased with average African ancestry
(Fig. 2a and Supplementary Fig. 18). One example of how this
breakdown could affect association is the rs12936231–rs4065275
haplotype and its association with ORMDL3 expression. Speci-
fically, Stein et al. notes that the rs12936231-C and rs4065275-G
alleles were associated with high expression of ORMDL3 in
peripheral blood cells from non-African populations, but the
rs4065275-G allele was not associated with expression of
ORMDL3 in Yoruban (African) lymphoblastoid cell lines. This
is possibly due to the rs12936231-C and rs4065275-G haplotype
almost always being present in this combination on non-African
haplotypes, while the rs12936231-G and rs4065275-G haplotype
in non-Africans was rare (3%). In contrast, the rs12936231-G and
rs4065275-G haplotype is common in Africans (19%)13. We
examined the rs12936231–rs4065275 haplotype for association
with asthma in the three local ancestry groups (0, 1, or 2 copies of
African ancestry), but no significant associations were observed in
any of the groups (Supplementary Table 16).
Finally, we note genome-wide significant SNPs at the
chromosome 17q12–q21 region in CAAPA ranged between
positions 37,908,867–38,089,717 (Fig. 2a), which included
the ORMDL3/GSDMB haplotype block (hg19, see Supplemen-
tary Table 9), at least 32 kb from the most significant SNP
(at position 37,876,835) in TAGC. However, in the TAGC
pediatric sub-group analysis the strongest association
was observed 3.6 kb proximal to GSDMB, so we speculate
the relatively strong association in CAAPA at the
ORMDL3/GSDMB region reflects the large proportion of
childhood onset asthmatics included in CAAPA (Supplemen-
tary Table 1). The ORMDL3/GSDMB region is strongly
associated with childhood onset asthma13,34, and to rule out
that the weaker associations in high African ancestry popula-
tions may be due to the inclusion of adult onset asthmatics in
some of the CAAPA studies, we re-tested the association
between the 22 candidate SNPs and asthma, using only those
studies where age of onset was available, or that were pediatric
studies. We compared the association results when including
versus excluding adult onset asthmatics, and the strength of the
associations remained marginal when adult onset asthmatics
were excluded (Supplementary Table 15).
Associations with total serum IgE. We also examined whether
genetic associations with asthma overlap with atopy by testing
lead SNPs from Table 2 for association with total serum IgE
(tIgE) using 4132 subjects for whom this phenotype was available
(CAAPA lead SNPs and lead SNPs from TAGC that replicated in
Table 3 Summary of tests for replication for two novel loci on chromosome 8 with p-values < 10−6 in the CAAPA meta-analysis
SNP Ethnicity Study Number non-asthmatics Number asthmatics p-value Effect direction
rs13277810 African ancestry CAAPA 7009 7645 3.20E−08 +
African American CARDIA 109 860 1.68E−01 +
African American MESA 200 1437 5.44E−01 −
African American ARIC 89 1636 5.24E−01 −
African American BioMe 391 1550 1.07E−01 −
Hispanic BioMe 519 1775 7.15E−04 +
rs13269769a European TAGC 19,954 107,715 9.55E−02b −
rs114647118 African ancestry CAAPA 7009 7645 2.70E−07 −
African American CARDIA 109 862 5.61E−02 +
African American MESA 200 1440 4.62E−01 −
African American ARIC 89 1638 7.18E−01 −
rs13277810 is a common variant that reached genome-wide significance, and rs114647118 is a low frequency variant with MR-MEGA association p-value < 10−6. rs13277810 was not available in the
TAGC meta-analysis summary statistics, but rs13269769, a SNP that has high LD with rs13277810 in the 1000 Genomes Project Europeans, was available. The rs114647118 association had low
imputation quality in BioMe, and was not included in the TAGC meta-analysis summary statistic dataset. Effect direction is defined in terms of the minor allele. The CAAPA discovery associations are
highlighted in bold font
ar2 with rs13277810 in TGP EUR= 0.994
bFixed-effect p-value
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CAAPA; associations were tested separately in cases and controls
and then combined using meta-analysis). Four of the SNPs
correlated with levels of tIgE in asthmatics (with the asthma risk
allele associated with increased levels of tIgE, Supplementary
Table 19), suggesting that these asthma risk alleles may lead to an
increased Th2 immune response. This includes SNP rs1420101
in the IL1R1 locus (a gene that is known to correlate with
eosinophilia35), SNP rs10519067 intronic to the RORA gene
(encoding a transcription factor that regulates the growth of
group 2 innate lymphoids, a key cell type in the memory Th2 cell
response36), and SNPs rs907092 and rs2952156 in the
chr17q12–21 locus. These results are consistent with previous
studies that have shown both shared and unique associations
between these phenotypes37–41.
Admixture mapping. In addition to performing an asthma
GWAS, we also leveraged local ancestry to identify regions of the
genome where ancestry from a particular ancestral population
was inherited more frequently in affected versus unaffected
individuals. This technique, called admixture mapping, can be
used as a complementary approach to association mapping in
admixed populations to uncover associations not detectable by
SNP tests alone42. Because the genetic structure of the Barbados
population is similar to that of African Americans (Fig. 1a and
Supplementary Fig. 1), and because of overlap in genotype array
coverage, we combined the African American studies genotyped
on the ADPC and the Barbados study (BAGS) and used this
combined dataset for admixture mapping discovery. CAAPA
studies genotyped on the MEGA, additional BAGS subjects
genotyped on Illumina’s Omni array, and African American
subjects from BioMe were leveraged to replicate our admixture
mapping discoveries. The distribution of p-values from the dis-
covery admixture mapping tests for association is summarized in
Supplementary Fig. 20 (local ancestry dose association p-values
reported by EMMAX). The QQ plot shows little evidence of
systematic test statistic inflation. The deflated inflation factor of
0.90 appears to be largely driven by 0.1 < p < 0.5, whereas the
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Fig. 2 Summary of the chromosome 17q12–21 region results. a This panel shows a locus zoom plot of the CAAPA meta-analysis results. Positions of 39
SNPs associated with asthma in TAGC Europeans that replicated in CAAPA (from Supplementary Table 13) are denoted by squares. The r2 between the
lead SNP rs907092 and the other SNPs with associations (represented by red, orange, green, light, and dark blue symbols) was calculated using African
American subjects from the CAAPA WGS reference panel. The r2 between the 39 SNPs in JAAS and GALA II are shown at the bottom of the plot, with
darker shades of grey representing higher LD. JAAS and GALA II are the studies with the highest and lowest proportions of African ancestry, respectively.
b A Forest plot of the effect size of rs907092 is shown in this panel. CAAPA datasets are ordered by decreasing percentage African ancestry. EAF effect
allele frequency. %YRI, CEU, and NAT represent estimated mean percentage of African, European, and Native American ancestry, respectively. c This
panel shows a box plot of the asthma risk allele odds ratio for 22 candidate SNPs in the chromosome 17q12–21 region. The 17 SNPs discussed by Stein
et al.13 were selected, and an additional five SNPs from the CAAPA meta-analysis, with MR-MEGA association p < 10−6 and r2 < 0.8 with all 17 selected
SNPs in the 1000 Genomes Project European and African populations, were also included. These five additional SNPs are also expression quantitative trait
loci for GSDMB/GSDMA/ORDLM3 in one or more GTEx tissues. The center line represents the median odds ratio, the box bounds represent the first and
third quartile of the odds ratio distribution, and the whiskers are 1.5 times the first and third quartile odds ratio. Outliers are represented by circles
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number of p < 0.02 is greater than expected, suggesting associa-
tion results are enriched with local ancestry segments showing
differences in ancestry between cases and controls. Only one
segment of local ancestry, ranging from base pair positions
134,149,974–134,300,365 on chromosome 6, crossed the multiple
testing threshold (see Methods). This segment falls within a local
ancestry peak on chromosome 6q22.31–23.2, with increased
African ancestry associated with increased risk of asthma (Sup-
plementary Table 20). Genes falling in this segment include the
Transcription Factor 21 (TCF21) and TATA-Box Binding Protein
Like 1 (TBPL1) genes. The TCF21 gene has been shown to be
differentially expressed in bronchial biopsies of asthmatics com-
pared to controls43. The most significant SNP showing associa-
tion in this region in the admixture mapping discovery group
(rs111966851, Supplementary Fig. 6) has a MAF of 0.308 and
0.006 in Africans and Europeans, respectively (n= 1322 AFR and
n= 1006 EUR TGP phase 3), which corroborates the idea that
African ancestry in this segment may increase risk for asthma.
For replication, local ancestry segments overlapping with the peak
segments were tested for association with asthma in CAAPA
studies with similar genetic structure to the discovery studies (i.e.,
African Americans and Jamaicans, see population structure in
Fig. 1a and Supplementary Fig. 1), additional BAGS (Barbados)
subjects, and African American subjects from BioMe. None of
these segments were associated with asthma (Supplementary
Table 21), and SNP rs111966851 (the most significant SNP in this
region in the admixture mapping discovery) was also not asso-
ciated with asthma in the CAAPA studies excluded from the
admixture mapping discovery (Supplementary Fig. 16).
Discussion
We report a large GWAS of asthma in African ancestry popu-
lations; prior studies included only 763–3037 asthmatic subjects4–
7. Eleven of the 18 loci recently identified in the TAGC meta-
analysis show evidence of association in CAAPA, including
strong evidence for four different regions. This includes the
region around STAT6 on chromosome 12q13, a novel region
identified by TAGC and not replicated to date, as well as the well-
known chromosome 17q12–21 region, which reached genome-
wide significance in our analysis. It has been posited that dis-
parities in asthma susceptibility can partly be explained by genetic
risk factors4,44,45. In recapitulating associations mainly discovered
in European ancestry populations (a result that has previously not
been well-quantified in the literature), our results suggest that at
the very least, common genetic variation may not strongly con-
tribute to asthma disparities. However, our data show the chro-
mosome 17q12–21 associations have smaller effect size
magnitudes on African ancestry haplotypes. In addition, we built
a genetic risk score for the 18 asthma loci reported by TAGC, and
found that although asthmatics had a statistically significant
higher risk score compared to controls (Supplementary Fig. 24),
the effect was too small to build a predictive risk score for asthma
in CAAPA.
In addition to recapitulating asthma genes discovered largely in
non-African populations, we identified two loci on chromosome
8 not previously reported by asthma GWAS, and through
admixture mapping identified a region on chromosome 6q22. In
our inclusion of the largest sample of African ancestry individuals
in our discovery GWAS, we were unfortunately limited in sample
sizes of African ancestry individuals available for replication with
consequent limitations in power. The most significant SNP on
chromosome 8p23 reached genome-wide significance and was
replicated in Hispanics from BioMe. However, our attempts to
replicate this same locus in African Americans were unsuccessful;
the number of cases compared to controls was considerably
smaller (4–18 times smaller) as the replication studies were not
primarily ascertained for asthma. Similarly, we also failed to
replicate the low frequency variant on chromosome 8q24 (only
398 African American asthmatics with genetic data were avail-
able) and the admixture mapping signal (only 845 cases were
available, of which 498 were African American).
The CAAPA meta-analysis includes data from 15 independent
studies and is the largest asthma GWAS focused on African
ancestry populations to date. Unfortunately, as is the case for
other complex diseases for which morbidity disproportionately
affects underrepresented and underserved populations46–48, a
legacy of underrepresentation or exclusion of minorities from
federally-funded studies has rendered comparatively robust non-
European datasets rare to nonexistent. A recent analysis of
ancestry represented in the GWAS Catalog12 concluded that non-
European, non-Asian groups combined account for less than 4%
of individuals included in the catalog46. The analysis also found
that African ancestry individuals contributed 7% of all catalog
associations, despite only comprising 2.4% of the catalog, high-
lighting the value of GWAS conducted in African ancestry
populations for enabling scientific discoveries. Furthermore, the
authors stressed the importance of assessing the generalizability
of genetic disease associations across populations, and the value
that low-LD African ancestry individuals contribute to multi-
ethnic fine-mapping of genetic associations. Despite the con-
siderable federal support for the CAAPA initiative, we do
recognize that the CAAPA sample size falls considerably short of
the recent mega studies comprised of asthma datasets in the
hundreds of thousands7,49. Furthermore, replication had to be
sought in studies not primarily ascertained for asthma and with
limited sample sizes. Important insights drawn from this study
include the demonstration that many of the genetic loci asso-
ciated with asthma in European ancestry populations may also be
at play in African ancestry populations, and a clearer under-
standing of the LD patterns among African ancestry populations
in 17q21. Potentially novel loci discovered by this meta-analysis
are as yet not replicated within this study, but warrant follow-up.
Importantly, the advent of institutional biobanks with access to
multi-ethnic patient populations50, as well as efforts by institu-
tions such as the National Institute of Health to reduce health and
research disparities51 promise to greatly expand representation of
well-characterized patients of African ancestry in the near future,
allowing for robust follow-up of these CAAPA findings. The
improved availability of African ancestry whole-genome sequence
imputation reference panels available through initiatives such as
the NHLBI-supported TOPMed program52 should also provide
high quality imputation of low and rare frequency variation in
African ancestry populations, which will empower future studies.
Lastly, we note better availability of other -omics datasets
representing diverse ethnicities, such as transcriptomic data in
tissue types relevant to asthma, will be needed to enable dis-
coveries by utilizing the next generation of analysis tools53–55.
Methods
Study oversight. NIH guidelines for conducting human genetic research were
followed. The Institutional Review Boards (IRB) of Johns Hopkins University
(GRAAD, BASS and BAGS), Howard University (CRAD and HUFS), Wake Forest
University (SARP), the University of California, San Francisco (coordinating center
for the SAGE II and GALA II studies), the Western Institutional Review Board for
the recruitment in Puerto Rico (GALA II Puerto Ricans), Children’s Hospital and
Research Center Oakland and Kaiser Permanente-Vallejo Medical Center (SAGE
II), the University of Chicago (CAG), University of the West Indies, Mona, Jamaica
and Cave Hill Campus, Barbados (BAGS), University of Mississippi Medical
Center (JHS), Henry Ford Health System (SAPPHIRE), the Universidad Cato ́lica
de Honduras in San Pedro Sula (HONDAS), Federal University of Bahia (BIAS and
ProAR), the University of Cartagena (PGCA), all reviewed and approved this
study. All participants provided written informed consent.
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Genome-wide ancestry estimation and analysis. Unrelated phase 3 1000 Gen-
omes Project (TGP) subjects of European ancestry (CEU, n= 84) and African
ancestry (YRI, n= 84), as well as unrelated Native American (NAT) subjects from
Mao et al.56 (n= 43), were used as reference panels for the genome-wide ancestry
analysis. A combined dataset of SNPs common to the reference panels plus all
genotyped SNPs in the CAAPA datasets (with <1% missing genotypes in each
dataset) were created, after which a LD pruning step was performed (leaving 20,482
SNPs). (Note for the SAPPHIRE dataset, the combined genome-wide ancestry
analysis described here was restricted to the 730 asthmatic cases for which ADPC
[African Diaspora Power Chip] data were available.) Principal components were
then formed from the genotypes of the CAAPA and reference subjects by the R
Bioconductor package GENESIS. GENESIS uses PC-AiR to calculate principal
components to account for cryptic and known relatedness between subjects57. PC1
distinguished African ancestry from European and Native American ancestry and
PC2 distinguished Native American ancestry from European and African ancestry.
The results are summarized in Supplementary Fig. 1. The combined dataset was
also used to estimate the proportion of genome-wide ancestry deriving from the
three source populations represented by the reference panels, for each CAAPA
subject. This was done using the software program ADMIXTURE. Because BAGS,
HUFS, and BIAS include families, and ADMIXTURE assumes all subjects are
unrelated, only the founders in these studies (n= 226, n= 997, and n= 179,
respectively) were included for the ADMIXTURE analysis. These results are
summarized in Fig. 1a and Supplementary Table 2. Finally, the GENESIS PCA was
repeated separately for each of the CAAPA datasets, excluding the reference
populations, using a set of LD pruned SNPs, in order to test for differences in
ancestry between cases and controls within each dataset. The association between
the first 2 PCs and asthma is summarized in Supplementary Table 2. As expected,
the first principal component explained most of the variance in the genetic data
(Supplementary Fig. 2) in all of the datasets. Relevant PCs were included in the
asthma association models, in order to adjust for population structure (see Asso-
ciation analysis).
Association analysis. Because the studies included in the primary asthma asso-
ciation analysis represent a diverse spectrum of African ancestry (Fig. 1a and
Supplementary Table 2), and had different objectives and differed in potentially
relevant factors such as age of onset and diagnosis (Supplementary Note 1 and
Supplementary Table 1), we performed tests for association separately for each
dataset, and then combined the association results using MR-MEGA, a novel meta-
regression approach that models allelic effects as a function of axes of genetic
variation11. In this way, heterogeneous associations across genetically distinct
populations are not penalized, and the degree of heterogeneity due to ancestry can
be assessed, as well as residual effects that may be due to differences in study
design.
Statistical models fitted to the GWAS+ADPC datasets. Logistic mixed effects
models were used to test for association between imputed allelic dosage and
asthma, using the GENESIS R Bioconductor package. GENESIS uses a penalized
quasi-likelihood approximation to the generalized linear mixed model. SNP asso-
ciation p-values are estimated using a score test, which tests for model fit
improvement if the SNP is added to the null model. GENESIS uses PC-relate to
estimate a kinship matrix excluding other sources of variance such as population
structure58, and PC-AiR to calculate principal components accounting for cryptic
and known relatedness between subjects57. The kinship matrix and principal
components were calculated using a dataset of LD pruned genotyped SNPs. This
kinship matrix was included as random effect in the null model, and principal
components were included as fixed-effect covariates (the first principal component,
as well as any of the top 10 principal components associated with asthma status
[p-value < 0.05], were included).
Statistical models fitted to the SAPPHIRE dataset. ADPC data were only
available for 730 SAPPHIRE asthmatics, but no controls. GWAS array data from
the Affymetrix Axiom AFR array were available for 1325 cases and 566 controls
(Table 1). The Henry Ford Health System group performed tests for association for
this study, and shared summary statistics with CAAPA. To generate the summary
statistics, logistic regression was used to test for association between imputed allelic
dosage and asthma, using the PLINK software package59,60. The GENESIS R
Bioconductor package was used to estimate a kinship matrix, to ensure that the
coefficient of relatedness between each pair of subjects was below 0.25. Principal
components were also calculated using GENESIS. Principal components included
in the regression models were chosen using the same strategy used in the CAAPA
GWAS+ADPC association analysis.
Statistical models fitted to the MEGA datasets. Asthma association tests in the
MEGA datasets used the same statistical models described for the GWAS+ADPC
datasets. However, because some of the populations genotyped on the MEGA have
a broader ancestry spectrum (Fig. 1a, Supplementary Fig. 1), the association ana-
lysis pipeline included as fixed-effect covariates the first principal component, any
other principal components identified by the elbow method (Supplementary Fig. 2)
as explaining a large percentage of variance, as well as any of the top 20 principal
components associated with asthma status [p-value < 0.05].
Processing and assessment of individual association results. First, association
results of SNPs with low imputation accuracy were removed from the individual
datasets. The chosen filter was informed by a study that quantified imputation
accuracy in African Americans61 and filtering was done based on minor allele
frequency (MAF) and the per-SNP estimation of the squared correlation between
imputed allele dosages and true unknown genotypes (Rsq). Associations between
asthma and SNPs with MAF ≤ 0.005 were excluded if Rsq ≤ 0.5, as were associa-
tions with SNPs with MAF > 0.005 if Rsq ≤ 0.3. SNPs with a minor allele count ≤10
were also excluded. Next, inflation factors and QQ plots were used to assess the
individual study association results (Supplementary Figs. 3 and 4). Large inflation
of these test statistics was not observed. All of the CAAPA datasets were therefore
included in the meta-analysis, described below.
Meta-analysis. MR-MEGA uses multi-dimensional scaling to infer genetic axes of
variation across studies, and models allelic effect across studies using a linear
regression model of the allelic effect of each study along each genetic axis of
variation, weighting the contribution of a study by the inverse variance of the allelic
effect from the study. The model is described in detail in the Materials and
Methods section of the MR-MEGA publication11. As input, the software requires
the association odds ratio (OR) and its 95% confidence interval (CI), which were
calculated per SNP and study as follows, where U is the Score statistic of the model
fitted by GENESIS for the SNP, and i is its variance:
OR ¼ eU=i ð1Þ
95%CI ¼ eU=i ± 1:96
ffiffi
1
p
=i ð2Þ
These formulas are based on recommendations from Zhou et al.62. For
SAPPHIRE, the odds ratio reported by the software was used as is, and the 95% CI
was calculated as follows, using the standard error (SE) reported by the software:
95%CI ¼ elogðORÞ± 1:96SE ð3Þ
The MR-MEGA software requires specification of the number of genetic axes of
variation to be used in the meta-analysis. Most of the CAAPA populations have
ancestry from African and European populations, with some Native American
ancestry (Fig. 1a). Because the mean Native American ancestry represented is
small, however, and the first axis generally separates populations of high and low
African ancestry (Supplementary Fig. 5), only 1 axis of genetic variation was used
in the meta-analysis.
Inverse-variance meta-analysis. MR-MEGA estimates p-values by comparing the
deviance of the regression model with coefficients equal to zero, to the deviance of
the model with the coefficients unconstrained, and combined odds ratios/effect
sizes across studies are not estimated. For this reason, all cross-study odds ratios
reported in this paper, e.g., Table 2 and the forest plots in the supplementary
material, were estimated using inverse-variance meta-analysis. Inverse-variance
meta-analysis was also used to combine association results of all the African
American studies in order to generate Supplementary Table 4, combined SNP
association results for the admixture mapping peak in the admixture mapping
discovery dataset (Supplementary Fig. 6), and assessing associations on chromo-
some 17q12–21 in studies with high and low African ancestry (Supplementary
Figs. 11 and 12, Supplementary Data 2).
Replication in cardiovascular disease studies. Imputed GWAS array data
(described previously63) from three cardiovascular disease studies with asthma
information were used to assess replication of novel associations in CAAPA
(CARDIA64, MESA65, and ARIC66, see Supplementary Note 2 and Table 3). The
imputed allelic dose of SNPs rs13277810 and rs114647118 was extracted, and
logistic regression (implemented in the R software packages) was used to test for
association between allelic dose and asthma. Principal components associated with
asthma (p-value < 0.1) were included as covariates in the models.
Replication in BioMe. Summary statistics of tests for association between GWAS
array data and asthma in African Americans and Hispanics from BioMe were also
used to assess replication (see Supplementary Note 2 and Table 3). These summary
statistics were generated using the logistic regression implementation in PLINK59.
ImpG-Summary67 and the CAAPA WGS reference panel (Supplementary Table 3,
Supplementary Note 3) were used to impute associations surrounding rs13277810,
separately for African Americans and Hispanics (predicted r2 for rs13277810 was
high, 0.911 in both the African American and Hispanic datasets). Associations for
the region surrounding the low frequency SNP rs114647118 were also imputed, but
the imputation quality of this SNP, as well as other low frequency SNPs in high LD
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with it, was insufficient to assess replication (predicted r2= 0.586 and 0.581 for all
SNPs assessed, in the African American and Hispanic datasets, respectively).
TAGC SNP-by-SNP comparison. The CAAPA meta-analysis was compared to the
TAGC multi-ethnic meta-analysis, the largest and most definitive asthma GWAS
to date7. The association results of the lead SNPs reported by TAGC were com-
pared by extracting the corresponding CAAPA meta-analysis p-values, and using
inverse-variance meta-analysis to calculate odds ratios and 95% CI for all SNPs
(Table 2 and Supplementary Table 12). Note that two of the TAGC lead SNPs were
not present in CAAPA: rs2855812 was filtered out of the CAAPA WGS reference
panel because this SNP is located in a segmental duplication region, and
rs11071558 was filtered out from the CAAPA reference panel because it is tri-
allelic. Because the largest population represented in TAGC is European (19,954 of
the 23,948 cases and 107,715 of the 118,538 controls), and because some of the
CAAPA studies were included in the TAGC multi-ethnic meta-analysis, a direct
comparison of association significance and effect size was only done for the TAGC
European meta-analysis, and not the multi-ethnic meta-analysis. Together with the
ancestry heterogeneity p-value estimated by MR-MEGA, this is also useful for
gleaning the effect of asthma-associated SNPs in Europeans versus Africans.
TAGC replication in CAAPA. In addition to the SNP-by-SNP comparison
described above, the TAGC summary statistics were downloaded and merged with
the CAAPA meta-analysis results. Associations of all SNPs with significant fixed-
effect p-values in TAGC Europeans were assessed in the CAAPA meta-analysis,
after applying a Bonferroni correction for the number of overlapping SNPs in the
merged dataset. A Bonferroni correction for the number of SNPs assessed in
CAAPA was applied as a stringent correction for claiming robust replication of loci
reported by TAGC in CAAPA (Supplementary Table 13).
Additional replication in CAAPA. Windows ±10 KB from each of the 18 TAGC
lead SNPs were extracted from the CAAPA meta-analysis results (±200 KB for the
chr17q12–21 locus, due to the extended LD in this region). A ±10-KB window
surrounding two SNPs reported as genome-wide significant in African ancestry
GWAS was also extracted5,6. A Bonferroni-corrected significance threshold for 20
tests (one for each of these prior loci) was used as a measure of additional evidence
of replication in the CAAPA meta-analysis (Fig. 1c and Table 2, loci not in bold
font).
LD block replication in CAAPA. SNPs within the same LD block and in high LD
with the TAGC lead SNPs (r2 > 0.8) in Europeans from the TGP were also selected
for comparison, and their association results were inspected (Supplementary
Table 18). In this way, no or marginal replication of TAGC lead SNPs in CAAPA
due to differences in LD patterns between Europeans and Africans can be assessed.
The LD block surrounding each lead TAGC SNP was identified using TGP phase 3
data, population EUR, representing European ancestry. Thus, the effect of SNPs
that may be causal in Europeans but not the lead SNP reported in the TAGC
European analysis can still be tested for replication in CAAPA. Flanking SNPs ±10
KB from each TAGC lead SNP with MAF >0.05 in the CAAPA WGS reference
panel and that intersected with the CAAPA meta-analysis association results as
well as TGP phase 3 variants were selected, and Gabriel’s algorithm implemented
in Haploview68,69 was then used to identify LD blocks present in the window of
SNPs. CAAPA meta-analysis p-values for SNPs falling in the LD block containing
the lead SNP, and that had r2 > 0.8 with the lead SNP, were extracted, and these
SNPs and their asthma associations are summarized in Supplementary Table 18.
The chr17q12–21 locus achieved genome-wide significance in CAAPA and was
therefore excluded from this analysis.
EVE replication sensitivity analysis. A sensitivity analysis of the African
ancestry-specific genome-wide association reported by the EVE consortium for
SNP rs11019996 was also done (Supplementary Table 12). CAAPA studies inclu-
ded in the EVE meta-analysis were meta-analyzed together, and all CAAPA studies
not included in the EVE meta-analysis were meta-analyzed together. MR-MEGA
was used for this meta-analysis, as CAAPA studies with relatively high proportions
of European ancestry could be included, without penalizing the strength of the
association should these high European ancestry populations show a different
pattern of association compared to populations with high African and low Eur-
opean ancestry.
Tests for association with total serum IgE. Lead SNPs from Table 2 (reported by
CAAPA, as well as TAGC SNPs with evidence for replication in CAAPA) were
tested for association with total serum IgE (tIgE), adopting the approach used in
the EVE consortium’s meta-analysis of genetic association with tIgE40. The analysis
was stratified based on asthma case-control status and originating study (eight
groups of asthmatics and six groups of controls, see Supplementary Table 1 for a
summary of the distribution of tIgE in these groups). Linear mixed-effect models
implemented in the R Bioconductor GENESIS software package were used for
association testing between the allelic dose at each SNP and Studentized residuals
of log10 transformed tIgE (adjusted for age and sex). Similar to the asthma
association models, the models included a kinship matrix as random effect and
principal components as fixed-effect covariates. Finally, association test statistics
from the analysis strata were combined using inverse-variance meta-analysis, to
yield combined statistics for non-asthmatics, asthmatics, and non-asthmatics+
asthmatics (Supplementary Table 19).
Admixture mapping discovery. Local ancestry inference was performed using
RFMix70, and the pipeline is described in Supplementary Note 12. Custom scripts
were used to convert the RFMix local ancestry calls to an EMMAX dosage TPED
file, where the encoded dosage is defined as having 0, 1, or 2 copies of African
ancestry at a particular local ancestry segment. Tests for association between the
local ancestry dosage values and asthma case-control status were then done using
the linear mixed-effect models implemented in the EMMAX software package.
Phenotypes for subjects from SAPPHIRE, which included only asthmatics and no
controls as well as the three population outliers identified by the genome-wide
ancestry analysis, were set to missing. These models included dataset as a fixed-
effect covariate, and a Balding-Nichols kinship matrix as random effect. The
method described by Gao et al. was used to estimate the number of effective tests
that should be used in a Bonferroni correction for multiple testing71. Briefly, a local
ancestry correlation matrix, and corresponding eigenvalues, was calculated using
local ancestry dosage values (0/1/2 copies of African ancestry) per chromosome.
The number of effective tests for a chromosome was then set to the number of
eigenvectors that explain 99.5% of the variance in the local ancestry data (for n
local ancestry segments, find the largest k such thatPk
i¼1 eigenvalues=
Pn
i¼1 eigenvalues  0:995). The total number of effective tests
was then set to the sum of the number of effective tests calculated for each of the 22
autosomes. Using this method, a Bonferroni-corrected p-value threshold of 0.05/
(262 total number of effective tests)= 1.9 × 10−4 was used to claim statistical
significance.
Admixture mapping replication. The segments including the start and end
position of the admixture mapping discovery peak (chr6:134,149,974–134,300,365)
were selected for replication. Logistic regression was used to test for association
between the number of copies of African ancestry (dosage value of 0, 1, 2) and case-
control status, separately for each replication dataset (BASS, BAGS, JAAS, and
BioMe). The base R package was used to fit the model to the BioMe data, adjusting
for the first and fifth principal components, as these principal components were
also associated with asthma status (p-values < 0.1). The R Bioconductor package
GENESIS was used to fit models to the BASS, BAGS, and JAAS dataset, including a
kinship matrix as random effect and principal components as fixed effects, as
described for the SNP association analysis. The results for the segment including/
closest to the midpoint of the admixture mapping discovery peak (134,225,170)
was combined using inverse-variance meta-analysis.
Admixture mapping power calculations. We used the Genetic Association Study
(GAS) Power Calculator72 to perform post-hoc power calculations for admixture
mapping. As BAGS and HUFS include related subjects, their effective number of
cases and controls were estimated as ncases ¼ 1=ð1þ 2rÞ and ncontrols ¼ 1=ð1þ 2rÞ,
where r is the mean kinship coefficient between relatives in the particular study73
(the kinship matrix estimated by GENESIS (see Statistical models fitted to the
GWAS+ADPC datasets) was used to calculate r; r ¼ 0:30 for BAGS, r ¼ 0:33 for
HUFS). Given 2380 cases and 3255 controls, at a significance level of p= 1.9 × 10−4,
disease prevalence of 0.1, disease allele frequency of 0.2 (the mean number of copies
of non-African ancestry), we had ≥89% power to detect a relative risk ≥1.20 in our
discovery dataset. For our replication dataset, given 777 cases and 2263 controls, at a
significance level of p= 0.05, disease allele frequency of 0.15 (accounting for the
lower mean number of copies of non-African ancestry in BAGS and JAAS), we
had ≥70% power to detect a relative risk ≥1.2. However, for a relative risk of 1.12
(the ratio of non-European local ancestry in controls versus cases for the segment
identified in the discovery), we only had 34% power for replication.
Software. Detailed information on the software packages and software versions
used for analyses are listed in Supplementary Table 24.
Data availability
The legacy GWAS array ADPC and MEGA data that support the findings of this
study have been deposited in dbGAP with the accession code phs001123.v2.p1.
These data can be accessed through dbGAP. Specific data use limitations: GRU-IRB
(General Research Use, IRB approval required). Only ADPC data are available for
the SAGE II, GALA II, and SAPPHIRE datasets; in addition, no phenotype data are
available for these three datasets. Summary statistics from the meta-analysis are
also available through the GWAS catalog12 [https://www.ebi.ac.uk/gwas/
downloads/summary-statistics].
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